Recursion Pharmaceuticals, Inc. (RXRX) Income Statement Analysis

See more : BCII Enterprises Inc. (BCII) Income Statement Analysis – Financial Results

Complete financial analysis of Recursion Pharmaceuticals, Inc. (RXRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Recursion Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Recursion Pharmaceuticals, Inc. (RXRX)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.recursion.com

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Metric	2023	2022	2021	2020	2019
Revenue	44.58M	39.68M	10.00M	3.41M	1.71M
Cost of Revenue	42.59M	48.28M	9.10M	63.32M	45.81M
Gross Profit	1.99M	-8.59M	896.00K	-59.91M	-44.10M
Gross Profit Ratio	4.46%	-21.66%	8.96%	-1,755.23%	-2,577.32%
Research & Development	241.23M	155.70M	135.27M	63.32M	45.81M
General & Administrative	110.82M	81.60M	57.68M	25.26M	18.95M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00
SG&A	110.82M	81.60M	57.68M	25.26M	18.95M
Other Expenses	0.00	-162.00K	-178.00K	-549.00K	-608.00K
Operating Expenses	352.05M	237.13M	192.78M	88.03M	64.15M
Cost & Expenses	394.64M	285.41M	192.78M	88.03M	64.15M
Interest Income	19.12M	6.25M	73.00K	336.00K	1.74M
Interest Expense	97.00K	55.00K	2.95M	1.36M	635.00K
Depreciation & Amortization	24.40M	19.49M	9.10M	4.44M	3.54M
EBITDA	-299.57M	-227.67M	-174.42M	-81.70M	-58.34M
EBITDA Ratio	-672.05%	-619.26%	-1,827.75%	-2,353.38%	-3,401.52%
Operating Income	-350.06M	-245.73M	-182.78M	-84.62M	-62.44M
Operating Income Ratio	-785.33%	-619.26%	-1,827.75%	-2,479.20%	-3,649.39%
Total Other Income/Expenses	17.93M	6.25M	-3.70M	-2.39M	562.00K
Income Before Tax	-332.13M	-239.48M	-186.48M	-87.01M	-61.88M
Income Before Tax Ratio	-745.10%	-603.50%	-1,864.79%	-2,549.25%	-3,616.54%
Income Tax Expense	-4.06M	-55.00K	-8.41M	876.00K	646.00K
Net Income	-328.07M	-239.42M	-178.07M	-87.88M	-62.53M
Net Income Ratio	-735.99%	-603.36%	-1,780.74%	-2,574.92%	-3,654.30%
EPS	-1.58	-1.36	-1.05	-0.52	-0.37
EPS Diluted	-1.58	-1.36	-1.05	-0.52	-0.37
Weighted Avg Shares Out	207.85M	175.54M	170.27M	165.79M	165.79M
Weighted Avg Shares Out (Dil)	207.85M	175.54M	170.27M	165.79M	165.79M

Is Recursion Pharmaceuticals Stock a Millionaire-Maker?

June 2, 2024fool.com

Recursion Pharmaceuticals hopes to use AI to accelerate drug discovery in the healthcare industry. its ambitious plans are still unproven, and the business has no approved products of its own.

Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool

May 29, 2024globenewswire.com

Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in CRISPR-Cas9 gene knockouts and a debiasing (correcting) algorithm. Published open-access today in Nature Genetics, “High-resolution genome-wide...

2 Cathie Wood Biotech Stocks That Could Be Worth the Risk

May 29, 2024fool.com

Cathie Wood likes to invest in risky biotech stocks. Ginkgo Bioworks has ambitions to disrupt biopharma manufacturing.

Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

May 24, 2024globenewswire.com

Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur

2 Stocks That Could 10x by 2035

May 24, 2024fool.com

Viking Therapeutics is looking to make noise in a fast-growing therapeutic area. Recursion Pharmaceuticals' approach could change the way we develop drugs.

Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock

May 23, 2024zacks.com

Recursion Pharmaceuticals (RXRX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

National Bank of Canada FI Buys 1,500 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 20, 2024https://www.defenseworld.net

National Bank of Canada FI raised its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 90.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,150 shares...